2018 Performance Report. GGA: Precision Medicine Pioneer

Transcription

1 2018 Performance Report GGA: Precision Medicine Pioneer Genetics Generation Advancement Corp. CEO Chris Tsai Ph.D. Stock Code:4160

2 Disclaimer This presentation and related information are based on internal and external information of GGA. GGA s actual results of operations, business developments, and financial conditions may differ from presented or implied forecast in this presentation, because GGA could not control various types of future risk. Predictive statements in this report only reflect forecast so far this year. This forecast may be changed by GGA at any time without notice.

3 1999 Bionet founded. Created the stem cell services in Taiwan 2008 GGA founded. Focus on precision medicine in genetic testing Milestone Awarded ASSTD (Assist Service Sector Technology Development) grant from Ministry of Economy The first publicly traded company specializing in genetic testing and scientific informatics in Taiwan with its IPO (4160-TW) 2014 Granted CAP Accreditation; Began to serve Japanese market Granted Affymetrix Service Provider certification; Granted Illumina Miseq CSPro certification The first to introduce the SNP microarray to the prenatal market, and expanding the service to pediatric disease diagnosis; Partnered with EXTEDO GmbH The laboratory has passed the examination for hepatitis C viral NS5A mutation screening NGS-based cell free tumor DNA testing; ddpcr for Cancer Following-up ; Whole Exome Sequencing

4 Precision Medicine: A Global Trend 2017, Missouri is the First State to Institute Newborn Screening for Spinal Muscular Atrophy 2018, Australian federal government announced the largest single investment of the screening for genetic diseases How to stop families playing genetic roulette

5 2008 GGA founded The Paradigm of Precision Medicine: Focusing on Genetic Testing and Scientific Informatics Focused on Genetic Testing and Scientific Informatics Solution Provided comprehensive genetic testing in whole lifespan: from preimplantation to prenatal stage and adult. Compiled big data, synthetic genomics and systems biology to operate scientific informatics solution. Collaborated with worldly known corporations, and refined technology and service abilities. Winner of the 2010 Promising Enterprise of the Taiwan Healthcare and Agricultural Biotech Industries Innovation and Excellence Awards The 1 st lab to offer PGD service in Taiwan as well as in Asia Awarded ASSTD grant from Ministry of Economy The 1st publicly traded company specializing in genetic testing and scientific informatics in Taiwan Named Deloitte s 2012 Technology Fast 500 Asia Pacific Companies. Granted CAP Accreditation. Began to serve Japanese market The 1 st Affymetrix Service Providercertified lab in Taiwan. The 1 st Illumina Miseq CSPro certified lab in Taiwan. The 1 st to introduce the SNP microarray to the prenatal market. Partnered with EXTEDO GmbH Passed the examination for hepatitis C viral NS5A mutation screening

6 5 Major Disciplines of Precision Medicine Maternal -fetal precision medicine Companion Diagnostics Pediatric Disease Diagnosis Non-invasive Cancer Screening Precision Health Management

7 GGA Performance Result 400, , , , , , , , , , ,548 營業收入 Revenue 毛利 Gross Profits 100,000 61,196 80,973 91,928 50, GGA s Revenue & Gross Profits Grow Gradually.

8 Consolidated Income Statement Unit: In Thousands of New Taiwan Dollars, Except Earnings per Share 1Q2018 1Q2017 YOY Amount % Amount % % Net revenue 93, % 89, % 4% Cost of good sold (51,491) (59,217) Gross profit 41,672 45% 30,503 34% 37% Operating expenses (29,698) (24,318) Income from operation 11,974 13% 6,185 7% 94% Non-operating income and expenses (55) 1,787 Income before income tax 11,919 13% 7,972 9% 50% Net income 9,974 11% 6,626 7% 51% Basic earnings per share

9 Consolidated Balance Sheet Unit In Thousands of New Taiwan Dollars 1Q2018 1Q2017 Amount % Amount % Cash and cash equivalents 216,988 58% 203,408 55% Notes and accounts receivable 50,003 13% 63,159 17% Inventories 34,541 9% 39,787 11% Property, plant and equipment 18,271 5% 21,560 6% Total assets 375, % 370, % Accounts payable 41,663 11% 49,371 13% Other current liabilities 10,252 3% 10,800 3% Total Liabilities 51,915 14% 60,171 16% Capital stock 242,470 65% 242,470 65% Total equity 323,340 86% 310,037 84%

10 Comprehensive Genetic Testing in Whole Lifespan Prevention Diagnosis Treatment

11 More than 1/5 Customers Return and Purchase Genetic Testing of GGA in 1 Year Over 1 million customers had experienced genetic testing services of GGA. This medical database allowed GGA to develop big data service. GGA provided customer service consistently to gain more profit Q1 Customer retention Rate 23% 77% 1 2 Multiple Testing Single Testing

12 Pioneer of Maternal-fetal Precision Medicine Stem Cell application Genetics testing Issued 1.05 Million Serving testing reports 79% IVF centers in Taiwan Serving clients in 11 Countries Serving ~40% Newborns every year 1 st One-stop Prenatal, Postnatal, Genetic counseling

13 GGA Growth Momentum Scientific Informatics Biotechnology and pharmaceutical industry regulatory information management Identify Trends Combination of biotech & informatics Medical tourism Growth Momentum R&D New product development Resource Integration NIPT+X Stem cell for aesthetic medicine Market Expansion Increase overseas agents

14 GGA Growth Momentum Scientific Informatics Biotechnology and pharmaceutical industry regulatory information management Identify Trends Combination of biotech & informatics Medical tourism Growth Momentum R&D New product development Resource Integration NIPT+X Stem cell for aesthetic medicine Market Expansion Increase overseas agents

15 Needs of Local and Fertility Tourism led High Growth Rate of Genetic Testing The government of Taiwan encouraged medical tourism such as fertility, aesthetic medicine and health examination. The growth of fertility tourism drove the GGA s genetic testing revenue growth. Reproductive medicine Aesthetic medicine Health Examination Local Medical Tourism

16 Fertility Tourism in Asia-Pacific Growing Rapidly

17 GGA Provided Genetic Testing to >79% IVF Centers in Taiwan, Served both Local and Medical Tourists High IVF Success Rate Taiwan is widely known for its world's highest success rates (about 36.7%) for In Vitro Fertilization(IVF) procedures. Competitive Medical Expenses Moreover, the price of IVF in Taiwan is three times cheaper than in the United States, while it is also the cheapest among nearby countries such as Japan, Hong Kong and China. The access to new technology and medication in Taiwan Cutting-edge technology (e.g. PGS/PGD) has been introduced for years in Taiwan, and many reproductive centers in Taiwan have practiced it. PGS/PGD assure transplantation of healthy embryos, and protect fetus from familial genetic diseases

18 The Increasing Amounts of IVF Cycles and Medical Tourism in Taiwan IVF Cycles 人工生殖治療週期數來台醫療總人數 ( 不含大陸 ) Medical Tourism 0 7 Important Medical Services for Medical Tourism - Aesthetic medicine - Craniofacial reconstruction - Reproductive medicine - Health examination - Liver transplantation - Joint replacement - Cardiovascular treatment

19 GGA Growth Momentum Scientific Informatics Biotechnology and pharmaceutical industry regulatory information management Identify Trends Combination of biotech & informatics Medical tourism Growth Momentum R&D New product development Resource Integration NIPT+X Stem cell for aesthetic medicine Market Expansion Increase overseas agents

20 GGA New Genetic Testing Services Product Life Cycle Stages Preimplantation Pregnancy Pediatrics Adults Expanded Carrier Screening Whole Exome / Genome Sequencing Liquid Biopsy Noninvasive Prenatal Testing (NIPT) Fetal-free DNA Noninvasive Cancer Testing Circulating tumor DNA NGS for Cancer Companion Diagnostics ddpcr for Cancer Following-up

21 Whole Exome / Genome Sequencing Disease diagnosis and precision medicine led the growth of Whole Exome / Genome Sequencing. GGA compiled massive maternal-fetal data, high genetic testing service quality to provide our customer complete service. Pediatrics Rheumatology Expanded Carrier Screening SNP array / WES / WGS Companion Diagnostics from single gene to WES/WGS From single to multiple genes Newborn Screening Health Examination

22 Expanded Carrier Screening Everyone might be the carrier for more then two genetic diseases. Expanded Carrier Screening common diseases in Asia IVF Obstetrics & Gynecology Ultrasound Health Evaluation Center Donation Center Expanded Carrier Screening 321 Preimplantation Prenatal Premarital Egg & Sperm Donation 321 common diseases worldwide

23 Treating Pure Genetic Diseases with Cord Blood Stem Cells Ministry of Health and Welfare of Taiwan announced that cord blood stem cells have been used to treat 29 diseases. And Expanded Carrier Screening detects 18 of them. Expanded Carrier Screening 50/321 Disease Confirmation Cord Blood Stem Cell Treatment *Other 11 diseases are not pure genetic diseases.

24 GGA Growth Momentum Scientific Informatics Biotechnology and pharmaceutical industry regulatory information management Identify Trends Combination of biotech & informatics Medical tourism Growth Momentum R&D New product development Resource Integration NIPT+X Stem cell for aesthetic medicine Market Expansion Increase overseas agents

25 International Marketing Plan The growth of medical tourism CAP-accredited and comprehensive genetic testing Increase of Genetic Testing Products Expansion of Genetic Testing market Agents Hospital

26 Genetic Testing Business Expedition: From Asia to Europe and the Americas The number of GGA s international customers has grown significantly and rapidly in recent years. Being recognized for high-standard genetic testing services, we have expanded our business from Asia to Europe and the Americas, including services to customers in Japan, Malaysia, China, UK, USA, Jordan, Brazil, and Saipan. Japan IVF Centers

27 GGA, An Ideal Candidate for Partnership with Multinational Pharmaceutical The 1 st publicly traded company specializing in genetic testing and scientific informatics in Taiwan

28 GGA Growth Momentum Scientific Informatics Biotechnology and pharmaceutical industry regulatory information management Identify Trends Combination of biotech & informatics Medical tourism Growth Momentum R&D New product development Resource Integration NIPT+X Stem cell for aesthetic medicine Market Expansion Increase overseas agents

29 Genetic Testing Drives the Growth of BIONET Group Result of NIPT+X Package - This package allowed pregnant women purchase cord blood storage package when they receive NIPT, and drives the growth of cord blood storage business effectively. Aesthetic Medicine - Skin Genetic Testing - Understood the process, application, and value of cell in aesthetic medicine Scientific Informatics Cord blood storage NIPT+X package Aesthetic medicine Scientific informatics

30 GGA Growth Momentum Scientific Informatics Biotechnology and pharmaceutical industry regulatory information management Identify Trends Combination of biotech & informatics Medical tourism Growth Momentum R&D New product development Resource Integration NIPT+X Stem cell for aesthetic medicine Market Expansion Increase overseas agents

31 GGA Scientific Informatics Product Portfolio Target Identification & Validation Lead Discovery & Optimization Toxicity & Safety Preclini cal Clinical Phase I, II, III & IV Manufact., Commerc., & Post-Market Intel. Compliance Efficiency LIMS: Inventory, Metrology, Sample Management, Work Request ELN LES/ EBR Process Monitoring Workflow, Integration, Standardization Quality Management System/eCTD publisher Innovation Research Chemical Design/Biomaterials Design Biomarkers ID ADMET & SAR Metabolomics & Pathways Genomics, Proteomics, & Systems Biology Life Sci. Mod. & Sim. High-Throughput Screening Intelligence Database Biological Entity Registration Clinical Trial Outcome Prediction Chemical Registration Drugs, PG, & PK databases Text, Chemical, Biological Data Mining in Literature & Patent databases

32 Scientific Informatics Business Expansion 2012 Implemented PMC suite to API company 2013~15 Semiconductor company adopt material studio Implemented ELN to Biotech companies Implemented ELN to Chemical industry 2016 Built up Sim.&Mod. Lab for Petroleum customer Implemented QMS to Medical Device Company Implemented Notebook to highest research institute 2017 Implemented ELN to Petroleum customer Built up LIMS for Pharmaceutical company

33 Precision Medicine: NGS Analysis Tool GGA, Official Partner of Dassault BIOVIA & QIAGEN, offers complete solution for NGS Analysis Whole Genome Sequencing Whole Exome Sequencing RNA-Seq, Transcriptome Analysis Genome, Transcriptome, Proteome, Metabolome

34 Precision Medicine NGS Application As partner of QIAGEN, GGA offers Level 2 & Level 3 NGS analysis tools. As a long-term partner of Dassault BIOVIA, GGA provides scientific AI and big data analysis service. CLCBIO NGS sequential assembling and visualization Metagenomics in personal medicine BIOBASE Human Gene Mutation Database (HGMD) Ingenuity Ingenuity Pathway Analysis (IPA) Ingenuity Variant Analysis (IVA) BIOVIA Pipeline Pilot, Scientific Data Management platform, NGS component for data analysis

35 Sustained Growth and Success of GGA Science Business Contribution Genetics Basic medicine Molecular biology Bioinformatics Big Data 2012 IPO Performance grows every year Rapid commercialization of latest technology Expand sales and service Issued 1.05 million testing reports Serving ~40% newborns every year Serving 79% IVF centers in Taiwan; the number of international customers to Taiwan for IVF treatment was rapid growth Assist in medication and reduce waste of resources

36 Q & A